Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Gemcitabine + Nab-paclitaxel + Nidanilimab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Gemcitabine||Gemzar||Difluorodeoxycytidine Hydrochlorothiazide|LY-188011||Chemotherapy - Antimetabolite 13||Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).|
|Nab-paclitaxel||Abraxane||ABI-007|Paclitaxel Protein-bound||Chemotherapy - Taxane 2||Abraxane (nab-paclitaxel) is an albumin-stablized version of paclitaxel, which binds microtubules and prevents depolymerization, resulting in decreased cell motility and division (NCI Drug Dictionary).|
|Nidanilimab||CAN04|CAN 04|CAN-04||Nidanilimab is a humanized monoclonal antibody that targets l1rap, which inhibits downstream signaling and blocks activation of NFkappa-B, thereby potentially inducing antibody-dependent cellular cytotoxicity, leading to decreased proliferation and increased death of tumor cells expressing IL1RAP (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03267316||Phase Ib/II||Nidanilimab Cisplatin + Gemcitabine + Nidanilimab Gemcitabine + Nab-paclitaxel + Nidanilimab||A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR)||Recruiting||11|